Takagi Hisato, Umemoto Takuya
Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Int J Cardiol. 2016 Oct 15;221:46-51. doi: 10.1016/j.ijcard.2016.07.006. Epub 2016 Jul 4.
To determine whether ≥moderate paravalvular aortic regurgitation (PAR) after transcatheter aortic valve implantation (TAVI) independently impairs overall survival and how much the impact on survival is, we performed an updated meta-analysis pooling not unadjusted but adjusted hazard ratios (HRs).
Databases including MEDLINE and EMBASE were searched through January 2016 using PubMed and OVID. Search terms included paravalvular or perivalvular; regurgitation, leak, or leakage; percutaneous, transcatheter, transluminal, transarterial, transapical, transaortic, transcarotid, transaxillary, transsubclavian, transiliac, transfemoral, or transiliofemoral; and aortic valve. Studies considered for inclusion met the following criteria: the design was an observational comparative study; the study population was patients undergoing TAVI; patients were divided into ≥moderate and ≤mild post-TAVI PAR; outcomes included ≥1-year all-cause mortality; and the adjustment method was a multivariate Cox proportional hazards analysis. An adjusted HR with its 95% confidence interval (CI) for ≥moderate post-TAVI PAR was abstracted from each individual study.
Our search identified 17 eligible studies including a total of 15,131 patients. A pooled analysis of all the 17 studies demonstrated a statistically significant 2.12-fold increase in mortality with ≥moderate PAR (HR, 2.12; 95% CI, 1.79 to 2.51; p<0.00001). Exclusion of any single study from the meta-analysis did not substantively alter the overall result disfavoring ≥moderate PAR. Although the statistical tests suggested funnel plot asymmetry, the corrected effect estimate from the trim-and-fill method demonstrated still a statistically significant 1.83-fold risk of mortality with ≥moderate PAR.
≥Moderate post-TAVI PAR is associated with a 2.12-fold increase in overall (≥1-year) all-cause mortality.
为了确定经导管主动脉瓣植入术(TAVI)后≥中度瓣周主动脉反流(PAR)是否会独立损害总生存率以及对生存率的影响程度,我们进行了一项更新的荟萃分析,汇总的不是未调整而是调整后的风险比(HRs)。
通过PubMed和OVID检索截至2016年1月的MEDLINE和EMBASE等数据库。检索词包括瓣周或瓣周的;反流、漏血或渗漏;经皮的、经导管的、经腔的、经动脉的、经心尖的、经主动脉的、经颈动脉的、经腋动脉的、经锁骨下动脉的、经髂动脉的、经股动脉的或经髂股动脉的;以及主动脉瓣。纳入考虑的研究符合以下标准:设计为观察性比较研究;研究人群为接受TAVI的患者;患者分为TAVI术后≥中度和≤轻度PAR;结局包括≥1年的全因死亡率;调整方法为多变量Cox比例风险分析。从每项个体研究中提取TAVI术后≥中度PAR的调整后HR及其95%置信区间(CI)。
我们的检索确定了17项符合条件的研究,共纳入15131例患者。对所有17项研究的汇总分析显示,≥中度PAR使死亡率有统计学意义地增加了2.12倍(HR,2.12;95%CI,1.79至2.51;p<0.00001)。从荟萃分析中排除任何一项单一研究都不会实质性改变不利于≥中度PAR的总体结果。尽管统计检验提示漏斗图不对称,但修剪填充法校正后的效应估计仍显示≥中度PAR使死亡风险有统计学意义地增加了1.83倍。
TAVI术后≥中度PAR与总体(≥1年)全因死亡率增加2.12倍相关。